Human CCL11 / Eotaxin Recombinant Protein Product Attributes
Product Type: Recombinant Protein
Recombinant CCL11 / Eotaxin based upon sequence from Human
Host: QP5770 protein expressed in E. coli.
Tag: GST
Protein Construction: A DNA sequence encoding the Homo sapiens (Human) CCL11 / Eotaxin, was expressed in the hosts and tags indicated. Please select your host/tag option, above.
Recommended Applications: Immunogen, Protein Standard, Cell culture, or Other Cell Biology Applications.
Application Notes: Please contact us for application specific information for QP5770.
Bioactivity Data: Untested
Full Length? Full Length
Amino Acid Sequence: GPASVPTTCC FNLANRKIPL QRLESYRRIT SGKCPQKAVI FKTKLAKDIC ADPKKKWVQD SMKYLDQKSP TPKP
Purity: Greater than 80% as determined by SDS-PAGE.
Reconstitution Instructions: Concentrated protein in liquid format. Reconstitution is not necessary.
Concentration of Human CCL11 / Eotaxin Protein:
Endotoxin Levels: Not determined.
Buffer: Tris-based buffer, 50% glycerol
Storage Conditions: Store at -20C to -80C.
Recombinant Human CCL11 / Eotaxin Protein General Information | |
---|---|
Alternate Names | |
CCL11, SCYA11 | |
Curated Database and Bioinformatic Data | |
Gene Symbol | CCL11 |
Entrez Gene ID | 6356 |
Ensemble Gene ID | ENSG00000172156 |
RefSeq Protein Accession(s) | NP_002977.1 |
RefSeq mRNA Accession(s) | NM_002986.2 |
UniProt ID(s) | P51671 |
UniGene ID(s) | Hs.54460 |
HGNC ID(s) | HGNC:10610 |
COSMIC ID Link(s) | CCL11 |
KEGG Gene ID(s) | hsa:6356 |
PharmGKB ID(s) | PA35543 |
General Description of Recombinant Human CCL11 / Eotaxin Protein. | |
In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3. |
Limitations and Performance Guarantee
This is a life science research product (for Research Use Only). This product is guaranteed to work for a period of two years when stored at -70C or colder, and one year when aliquoted and stored at -20C.
There are no reviews yet.